September 2015

Integra’s membrane speeds DFU healing, company inks deal to sell Tornier ankles

Wound Repair & Regeneration on August 22 epublished results from a pivotal clinical trial showing Integra LifeSciences’s bilayer membrane skin regeneration system closed nonhealing diabetic foot ulcers (DFUs) faster than standard care.

The 32-site trial randomized 307 patients with at least one nonhealing DFU to IDRT (Integra Dermal Regeneration Template, n = 154) or .9% sodium chloride gel (n = 153). IDRT significantly outperformed the sodium chloride gel in median time to complete DFU closure (43 days vs 78 days) and rate of wound size reduction per week (7.2% vs 4.8%).

Integra’s CEO Peter Arduini noted the Plainsboro, NJ-based company is on track to commercialize IDRT for the DFU market in mid-2016.

In September, Integra announced it had inked a definitive agreement to acquire the US rights to Dutch company Tornier’s Salto Talaris and Salto XT ankle replacement and silastic toe replacement products for an undisclosed cash payment.

The transaction is subject to approval by the Federal Trade Commission and the closure of the pending merger of Tornier, which has its global headquarters in Amsterdam, and Memphis, TN-based Wright Medical Group.

Leave a Reply

Your email address will not be published.

This site uses Akismet to reduce spam. Learn how your comment data is processed.